Biomarkers
Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
Scientific Reports 2024 July 10 [Link] Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of…
Read MoreGenomic and T cell repertoire biomarkers associated with malignant mesothelioma survival
Thoracic Cancer 2024 May 27 [Link] Muwen Nie, Zhao Sun, Ningning Li, Liangrui Zhou, Shuchun Wang, Mingming Yuan, Rongrong Chen, Lin Zhao, Ji Li, Chunmei Bai Abstract Background: Malignant mesothelioma (MM) is an exceedingly rare tumor with poor prognosis due to the limited availability of effective treatment. Immunotherapy has emerged as a novel treatment approach…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreBAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
JTO Clinical and Research Reports 2024 March 29 [Link] Duo Xu, Yanyun Gao, Haitang Yang, Marc Spils, Thomas M Marti, Tereza Losmanová, Min Su, Wenxiang Wang, Qinghua Zhou, Patrick Dorn, Yongqian Shu, Ren-Wang Peng Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare and universally lethal malignancy with limited treatment options. Immunotherapy with immune checkpoint…
Read MorePleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report
European Journal of Histochemistry 2024 May 2 [Link] Claudia Lombardo, Grazia Maugeri, Agata Grazia D’Amico, Giuseppe Broggi, Rosario Caltabiano, Veronica Filetti, Serena Matera, Velia D’Agata, Carla Loreto Abstract Pleural mesothelioma is a devastating malignancy primarily associated with asbestos exposure. However, emerging evidence suggests that exposure to fluoro-edenite fibers, a naturally occurring mineral fiber, can also…
Read MoreCirculating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma
Thoracic Cancer 2024 April 16 [Link] Juuso Paajanen, Ahmed Sadek, William G Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R Gill, Raphael Bueno Abstract Background: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers…
Read MorePrognostic significance of inflammation scores in malignant mesothelioma
European Review for Medical and Pharmacological Sciences 2024 March [Link] E Mutlu, M Inanc Abstract Objective: The relationship between inflammatory markers and survival in many cancers has been investigated previously. Inflammatory markers may also offer the possibility of predicting surveillance in patients with malignant mesothelioma. Our study seeks to enhance comprehension of how variables such…
Read MoreCHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…
Read MoreBAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma
Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…
Read More